Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Why Is Aclaris Therapeutics (ACRS) Stock Down -1.94% Today?

Why Is Aclaris Therapeutics (ACRS) Stock Down -1.94% Today?

Key Takeaways

  • ACRS slipped 1.94% to $3.54 in early Tuesday trading, down $0.07 from Monday's $3.61 close, extending a two-session decline of roughly 10%.
  • The primary catalyst is a fresh analyst downgrade: Wedbush moved the shares to Neutral from Outperform and slashed its 12-month price target to $3 from $8.
  • The secondary driver is continued fallout from Monday's disclosure that the Phase 2 ADMIRATION trial of bosakitug missed both its primary and secondary endpoints in atopic dermatitis, a session in which the stock fell 8.04%.
  • Broader context: the setback hit a high-beta, clinical-stage micro-cap already down nearly 46% from its 52-week high of $6.60, with the move unfolding alongside softness across small-cap biotechnology.
  • Analyst opinion is split, with several firms reiterating constructive ratings even as Wedbush moved to the sidelines.
  • News Significance Score: 27/100 - A moderate rating downgrade met an unusually small price response for this volatile name.
  • Investors can dig deeper into Price Targets, Earnings and Forecast pages for additional detail on the name.
  • Explore the Trending AI Robots page to see which automated strategies are performing best in the current market.

Opening Summary

Aclaris Therapeutics, Inc. (ACRS) is a clinical-stage biopharmaceutical company developing small-molecule kinase inhibitors and antibody therapies for immuno-inflammatory diseases, with a pipeline led by modzatinib (ATI-2138), the bispecific antibody ATI-052 and the anti-TSLP antibody bosakitug. Shares were quoted at $3.54 shortly after Tuesday's opening bell, down 1.94% from the prior session's close of $3.61, confirming a move to the downside. The immediate reason cited by markets is a downgrade to Neutral from Outperform at Wedbush, paired with a price target cut to $3 from $8, which landed before the opening bell and reinforced the selling pressure set off by Monday's failed Phase 2 atopic dermatitis readout.

Wedbush Downgrade Sets the Tone

The most concrete piece of fresh news driving Tuesday's tape is the Wedbush rating change. The firm moved Aclaris to Neutral from Outperform and cut its target to $3 from $8 — a level below the current share price, implying the analyst now sees limited near-term upside. The note also raised doubts about whether the FDA will accept the seamless Phase 2b/3 trial design the company proposed in late October and flagged rising competitive noise in eosinophilic esophagitis, the indication to which ATI-052 has been redirected. A target roughly 60% below the prior level is a meaningful signal for a company with a market capitalization of about $560 million, and it removes one of the more aggressive bullish anchors that had supported the stock through the autumn.

Clinical Setback Still Dominates the Narrative

Tuesday's decline is best understood as an aftershock. On Monday, Aclaris disclosed that the ADMIRATION trial of bosakitug did not achieve its primary endpoint of percent change in EASI score at week 24, and secondary endpoints were also missed. Management said the result was consistent with the broader history of TSLP monotherapy in atopic dermatitis and indicated the company will pursue business-development options for the asset rather than fund further internal development. Shares gapped down and closed 8.04% lower on volume roughly three times the 60-day average. Selling carried into a second session as holders reassessed the equity story without a near-term biologic catalyst in the largest commercial indication.

A Pipeline Pivot With High Stakes

The bull case now rests almost entirely on the oral and bispecific programs. Aclaris simultaneously launched the Phase 2b ALPHA trial of modzatinib in moderate-to-severe lichen planus, a dual ITK/JAK3 inhibitor that carries FDA Fast Track designation and would be the first mechanistically complete oral therapy for a disease with no approved options. The company also completed IND-enabling work on the oral ITK inhibitor ATI-9494 and plans to file its IND this quarter, while a Phase 2b study of ATI-052 in eosinophilic esophagitis is targeted for the first quarter of 2027. Those milestones are real, but they sit quarters away — a timeline that leaves little to support the stock on a day when an analyst steps back.

Market Context and Trading Activity

Volume has been light so far, with only a few thousand shares changing hands in the opening minutes, so the early percentage move should be read as a thin-tape indication rather than a settled close. The broader context is more telling: Aclaris averages roughly 1.85 million shares a day over the past 60 sessions, and Monday's session traded more than triple that pace. The stock remains in a well-defined downtrend, having fallen from a late-August close of $6.54 through an October slide to the current mid-$3s, and it is now trading below its 20-day and 50-day moving averages. The move is company-specific rather than sector-driven — the pressure traces directly to trial data and the downgrade, not to a broad risk-off session in biotechnology.

News Significance Score

The score runs from 0 to 100, where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news paired with an extreme, rare price move. Aclaris earns 27 out of 100. The verified news — a downgrade to Neutral and a target cut to $3 from $8 — is material relative to a company of this size, but it is a rating change layered on a clinical failure already disclosed a session earlier rather than a new fundamental shock. The price response was anything but extreme: a 1.94% decline is about half the 3.86% average absolute daily move of the past 60 sessions, and 39 of those 60 sessions produced equal or larger swings. Modest news strength and a routine move combine into a low score.

What Comes Next for ACRS

Attention now shifts to execution on the remaining pipeline. Investors will watch enrollment progress in the Phase 2b ALPHA trial of modzatinib in lichen planus, the planned ATI-9494 IND submission this quarter, and any regulatory feedback on the proposed seamless Phase 2b/3 design for ATI-052. A decision on a second indication for ATI-052 is expected before the end of 2026, with atopic dermatitis and asthma still under consideration. Analyst expectations remain wide-ranging, and further rating revisions are plausible as models are reset around a smaller pipeline. The key risks are cash runway following this year's financings, the binary nature of the next clinical readout, competitive pressure in eosinophilic esophagitis, and the possibility that business-development efforts for bosakitug fail to produce a partner. Quarterly results are the next scheduled update.

Trending AI Robots

Tickeron's Trending AI Robots page offers a curated view of automated trading strategies that are working right now. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in this section, which makes it a practical starting point for screening ideas. The bots differ by strategy, timeframe, performance metrics and the symbols they trade, so investors can compare approaches and find one aligned with their own objectives. Visit the page to review the current leaders and see how they are positioned.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ACRS

Aroon Indicator for ACRS shows an upward move is likely

ACRS's Aroon Indicator triggered a bullish signal on November 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator showed a similar pattern. In 197 of the 232 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRS's RSI Indicator exited the oversold zone, 21 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on October 21, 2026. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in 36 of 43 cases over the following month. The odds of a continued upward trend are 84%.

Following a +17.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in 222 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRS as a result. In 71 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The 50-day moving average for ACRS moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

ACRS broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.608) is normal, around the industry mean (3.592). P/E Ratio (-6.724) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ACRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interesting Articles
A.I. Advisor
published General Information

General Information

a manufacturer of novel dermatological therapies

Industry Biotechnology

Industry
Pharmaceuticals Other
Address
701 Lee Road
Phone
+1 484 324-7933
Employees
73
Web
https://www.aclaristx.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.